Baseline Cardiac Biomarker Levels as Predictors of Cancer Risk in the MESA Cohort
In the MESA cohort, higher baseline levels of hs-cTnT and NT-proBNP predicted an increased risk of incident cancer, with no significant differences by race/ethnicity or sex.
Authors
- Michael Joseph Blaha (ORCID: https://orcid.org/0000-0001-5138-9683)
- En‐Hua Yang (ORCID: https://orcid.org/0000-0001-6066-8254)
- Zeina Dardari (ORCID: https://orcid.org/0000-0001-6026-3329)
- Erin D. Michos (ORCID: https://orcid.org/0000-0002-5547-5084)
- João A.C. Lima (ORCID: https://orcid.org/0000-0001-8756-6995)
- Spencer Hansen (ORCID: https://orcid.org/0000-0003-0853-4907)
- Karol E. Watson (ORCID: https://orcid.org/0000-0003-3658-6165)
- Christopher R. deFilippi (ORCID: https://orcid.org/0000-0002-0660-4943)
- W. Craig Johnson (ORCID: https://orcid.org/0000-0002-3161-3753)
- Quinn White
- Xinjiang Cai (ORCID: https://orcid.org/0000-0001-8933-7133)
- Matthew J Budoff
- Robyn L. McClelland
Institutions
- Johns Hopkins University (US)
- University of California, Los Angeles (US)
- University of Washington (US)
- UCLA Health (US)
- Johns Hopkins Medicine (US)
- UCLA Medical Center (US)
- Johns Hopkins Hospital (US)
- Alaska Heart and Vascular Institute (US)
- Harbor–UCLA Medical Center (US)
Publication Details
- Journal
- JACC Advances
- Published
- 2025-06-16
- DOI
- https://doi.org/10.1016/j.jacadv.2025.101884
- Citations
- 2
- Primary Topic
- Chemotherapy-induced cardiotoxicity and mitigation
- Type
- article
- Field-Weighted Citation Impact
- 2.78
Funders
- Amgen
- Bristol-Myers Squibb
- Eli Lilly and Company
- Pfizer
- Edwards Lifesciences
- CSL Behring
- National Institutes of Health
- Abbott Diagnostics
- National Heart, Lung, and Blood Institute
- Janssen Research and Development
- National Center for Advancing Translational Sciences